Bioequivalence Study Between "Dong-A Atorvastatin Tab" and "Lipitor Tab"

Inclusion Criteria: 1. A person who aged 19 or older at the time of screening 2. BMI of 18 to 30 (BMI calculation: kg/m2) * Males weighing 50kg or more * Females weighing 45kg or more 3. No congenital or chronic diseases or pathological symptoms 4. A person who is judged to be suitable for the study by the investigator based on the clinical laboratory examination 5. A person who has fully understood the contents of the consent form for the study and signed the consent form voluntarily and recorded the date of signature 6. A person who agreed to use contraception from the first administration of IP to a week after the last administration of IP Exclusion Criteria: 1. A person who has taken a drug that significantly induces (e.g., barbital) or inhibits the drug metabolic enzyme within 30 days prior to the first administration of IP 2. A person who has participated in other clinical trials within six months prior to the first administration of the IP 3. A person who has had whole blood transfusion within 2 months or the apheresis within 2 weeks before the first administration of IP 4. A person who has medical history of gastric resection that can affect the drug absorption 5. A person with a history of regular alcohol intake within a month prior to the first administration of the IP: * Male: More than 21 cups/week * Female: More than 14 cups/week (1 cup: 50 ml of soju, 250 ml of beer, 30ml of spirits) 6. A person who is hypersensitive to any of the IP components, taking glecaprevir, pibrentasvir, has active hepatic disease, Blood AST (GOT) or ALT (GPT) levels exceed the upper reference range limit by 3 times, muscle disease, or any genetic symtoms such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption 7. A person who has medical history of mental disease 8. A person who is judged not to be suitable for the study by the investigator 9. Lactating or possibly pregnant women